Osmetech's eSensor XT-8 System wins R&D 100 Award

 

TIDMOMH 
 
 
Osmetech PLC 
30 July 2009 
 
? 
30 July 2009 
Osmetech plc ("Osmetech" or the "Company") 
 
 
Osmetech's eSensor XT-8 System wins 'R&D 100 Award' 
 
 
Osmetech plc (OMH.L), the international molecular diagnostics company, announces 
that its eSensor XT-8 System has been selected by an independent judging panel 
and editors of R&D Magazine as a recipient of a 2009 R&D 100 Award. This award, 
also called the "Oscars of Invention", recognizes the 100 most technologically 
significant products introduced globally in the past year across all market 
sectors.  Since 1963, the R&D 100 Awards have identified revolutionary 
technologies newly introduced to the market.  Previous award winners include 
many household names including the automated teller machine, halogen lamp, fax 
machine, liquid crystal display, printer, and HDTV. 
 
 
This award for Osmetech and comes only one month after the eSensor XT-8 System 
was named as a gold winner of the 2009 Medical Design Excellence Awards. 
 
 
The FDA-cleared eSensor XT-8 System produces results in less than 30 minutes 
detecting multiple genetic markers from a prepared patient sample. Using 
proprietary electro-chemical technology, the self-contained cartridge consumable 
contains 72 gold-plated electrodes, each acting as independent DNA microsensors 
on a printed circuit board. 
 
 
The instrument provides an easy-to-use graphical, touch screen interface, a 
small footprint, requires limited operator training, low maintenance and no 
instrument calibration. The XT-8 is a complete random access system in which 
each cartridge slot operates independently supporting the use of a wide variety 
of tests. The system's modular and expandable design enables the capacity 
requirements of high throughput users to be met. 
 
 
Chris Gleeson, Chairman, Osmetech plc, said: 
 
 
"We are delighted that our eSensor XT-8 System has received this 
prestigious global award. This is further recognition for our innovative, 
practical and cost-effective platform which is rapidly gaining market acceptance 
with FDA cleared tests now available for Warfarin Sensitivity and Cystic 
Fibrosis Genotyping." 
 
 
 
 
+--------+--------+-------------------------+--+----------------+ 
| Osmetech plc                              | [phone]   | 
|                                           | 6027              | 
+-------------------------------------------+-------------------+ 
| David Sandilands, Chief Financial Officer |  |                | 
+-------------------------------------------+--+----------------+ 
|        |        |                         |  |                | 
+--------+--------+-------------------------+--+----------------+ 
| Madano Partnership                        | [phone]   | 
|                                           | 4000              | 
+-------------------------------------------+-------------------+ 
| Matthew Moth, Mark Way                    |  |                | 
+-------------------------------------------+--+----------------+ 
|        |        |                         |  |                | 
+--------+--------+-------------------------+--+----------------+ 
| Canaccord Adams Limited                   | [phone]   | 
|                                           | 6500              | 
+-------------------------------------------+-------------------+ 
| Robert Finlay                             |  |                | 
+-------------------------------------------+--+----------------+ 
| Henry Fitzgerald-O'Connor                 |  |                | 
+--------+--------+-------------------------+--+----------------+ 
 
 
 
 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAUKVVRKARBUAR